HC Wainwright Reiterates “Buy” Rating for Hemab Therapeutics (NASDAQ:COAG)

Hemab Therapeutics (NASDAQ:COAG)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $40.00 price objective on the stock. HC Wainwright’s price target would indicate a potential upside of 27.31% from the stock’s current price.

COAG has been the subject of several other reports. Jefferies Financial Group assumed coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They set a “buy” rating and a $39.00 price target for the company. Wall Street Zen upgraded shares of Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. The Goldman Sachs Group initiated coverage on Hemab Therapeutics in a report on Tuesday, May 26th. They set a “buy” rating and a $36.00 price objective for the company. Evercore initiated coverage on shares of Hemab Therapeutics in a report on Tuesday, May 26th. They issued an “outperform” rating and a $50.00 price objective for the company. Finally, Zacks Research upgraded Hemab Therapeutics to a “hold” rating in a research note on Wednesday, May 27th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $41.40.

Hemab Therapeutics Stock Performance

COAG stock traded up $3.70 during mid-day trading on Friday, reaching $31.42. 96,027 shares of the stock traded hands, compared to its average volume of 254,728. Hemab Therapeutics has a 52 week low of $23.00 and a 52 week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last released its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) earnings per share (EPS) for the quarter.

Insider Buying and Selling at Hemab Therapeutics

In other news, Director Ra Capital Management, L.P. purchased 2,675,000 shares of the business’s stock in a transaction on Monday, May 4th. The stock was purchased at an average cost of $18.00 per share, with a total value of $48,150,000.00. Following the acquisition, the director directly owned 6,149,096 shares in the company, valued at approximately $110,683,728. This trade represents a 77.00% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought a total of 2,970,541 shares of company stock valued at $55,459,603 in the last three months.

Hemab Therapeutics Company Profile

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.